Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.

Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.

As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.

Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.

Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.

生物标志物是生理或疾病过程的物理、功能或生化指标。这些关键指标可为确定疾病预后、预测对治疗的反应、不良事件和药物相互作用以及确定基线风险提供重要信息。人们对生物标志物研究兴趣的激增推动了现代医疗实践中新型预测、诊断和预后产品的开发，生物标志物在新药的发现和开发中也发挥着越来越重要的作用。为了充分发挥生物标志物的效用，我们需要更好地了解疾病机制以及疾病机制、治疗干预措施和拟议的生物标志物之间的相互作用。然而，在尝试系统地评估生物标志物的优缺点时，我们正在进入新的、充满挑战的领域。

《医学中的生物标志物》（ISSN 1752-0363）是一本同行评审的快速出版期刊，提供有关我们对生物标志物的理解进展及其在医学中的潜在和实际应用的评论和分析。该期刊有助于将我们的研究知识转化为临床应用，从而提高医疗实践的有效性。

随着生物标志物在医学和药物开发中的科学原理和监管认可度越来越充分，《生物标志物在医学中》为这一日益重要的领域的所有参与者提供了一个平台，以交流和讨论与潜在效用和应用有关的所有问题。

每期都包含各种内容，为研究专业人士提供全面的报道。文章包括客座社论、访谈、评论、研究文章、观点、优先论文评估、特别报告、病例报告、会议报告和公司简介。评论报道根据治疗效用领域分为主题部分，有些期刊包括关于热门领域的主题部分。

《生物标志物在医学中》为所有对生物标志物的识别、其作用的阐明以及其在现代医学中的应用的正规化和批准感兴趣的专业人士提供了一个评论和辩论的平台。 《医学生物标志物》的受众包括学术和工业研究人员、临床医生、病理学家、临床化学家和监管专业人员。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-医学：研究与实验领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为1.9，平均审稿速度为 较慢,6-12周 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。